The direct effects of angiotensin II (Ang II) on human cardiac muscle were investigated using isolated trabecular muscles from failing and functionally normal hearts. (Circulation 1990;82:1973 -1984 T wo developments in the field of cardiovascular physiology have renewed interest in the effects of angiotensin II (Ang II) on the myocardium. First, the observation that angiotensin converting enzyme inhibitors such as captopril are more efficacious in treating heart failure patients than direct-acting vasodilators1,2 suggests that the renin-angiotensin system or its perturbation may be involved in heart failure, although the mechanisms involved remain to be defined. Second, evidence for the existence of localized tissue renin-angiotensin systems3 and the demonstration that such a system
T wo developments in the field of cardiovascular physiology have renewed interest in the effects of angiotensin II (Ang II) on the myocardium. First, the observation that angiotensin converting enzyme inhibitors such as captopril are more efficacious in treating heart failure patients than direct-acting vasodilators1,2 suggests that the renin-angiotensin system or its perturbation may be involved in heart failure, although the mechanisms involved remain to be defined. Second, evidence for the existence of localized tissue renin-angiotensin systems3 and the demonstration that such a system exists in the myocardium3,4 raise the possibility that locally generated Ang II may act in an autocrine or paracrine fashion to directly modulate cardiac function by a mechanism independent of its peripheral effects.
Although it has long been recognized that Ang II can have an indirect effect on the heart due to the reflex response to its hemodynamic actions,35 there are at least two other mechanisms by which Ang II might directly influence cardiac output. Circulating Ang II may alter the inotropic state of the myocardium by activating myocardial Ang II receptors. Alternatively, Ang II produced locally within the myocardium may activate the receptors. The question of whether there is a direct action of Ang II on cardiac muscle and the relation between such an Singer'1 have shown that Ang II receptors in the guinea pig heart are not coupled to an inotropic response. Despite the apparent lack of an inotropic response to Ang II in the myocardium of the guinea pig" and the adult rat,12 a positive inotropic response to Ang II has been demonstrated in cardiac muscle from the cat, rabbit, calf, and chicken and in isolated, perfused hearts from normal and cardiomyopathic hamsters. [6] [7] [8] [9] 17, 18, 21 In isolated canine myocardial preparations, however, Kobayashi and coauthors10 reported a positive inotropic response to Ang II in some patients and no response or a negative inotropic response in others.
The variability and species specificity of the myocardial inotropic response to Ang II led us to investigate the nature of the response to Ang II in cardiac muscle isolated from human hearts. We report the results of our studies on 12 atrial trabeculae from the functionally normal hearts of eight human surgical patients as well as 16 atrial and 15 ventricular trabeculae from the failing hearts of 10 human cardiac transplant patients. The results directly demonstrate that Ang II has a positive inotropic effect on both failing and nonfailing human cardiac muscle and further suggest that the inotropic effect may be greater in atrial than in ventricular muscle. Due to the inability to procure ventricular tissue from functionally normal human hearts, we were unable to determine whether the relatively small inotropic response observed in ventricular muscle was unique to the failing heart. For this reason, we extended our studies to the ventricle of the Syrian cardiomyopathic hamster, a well-described animal model of heart failure, and its control. Although these studies confirmed that the inotropic response to Ang II is also relatively small in hamster ventricular tissue, they also demonstrated that the increase in tension produced by Ang II is significantly diminished in cardiac muscle from myopathic hearts compared with that from normal hearts.
The results support the hypothesis that Ang II, whether circulating or produced locally within the myocardium, can act as a positive inotropic agent to enhance the contractility of human cardiac muscle and suggest that the relative responsiveness to Ang II can be regulated by heart failure and other unidentified factors.
Methods

Tissue Preparation
One group of human myocardial trabeculae was obtained from the explanted hearts of patients with cardiac failure undergoing transplantation at the Cleveland Clinic Foundation, as described previously. 22 The time from surgical excision of the heart until its arrival in the laboratory ranged from 20 to 45 minutes. During transport to the laboratory, the heart was maintained in ice-cold, oxygenated cardioplegia solution of the following composition (mM): NaCl 147.16, MgCl2 16 .00, KCl 20.0, NaHCO3 10.0, CaCl2 2.25, and procaine 1.0. Once in the laboratory, the heart was placed in cold (8- (Cherry Hill, N.J.). Ascorbic acid (10`M) was added to the isoproterenol to prevent oxidation. DL-Propranolol (Sigma Chemical, St. Louis, Mo.) was dissolved in deionized water. Phentolamine mesylate (CIBA Pharmaceutical Company, Summit, N.J.) was reconstituted with deionized water immediately before use.
Measurement of Heart Function In Vivo
Percent fractional shortening of the left ventricular wall [%FSH(LV)] for each of the patients from whom tissue was obtained was measured from the last echocardiogram obtained before transplant or cardiac surgery. Standard M-mode and twodimensional echocardiograms were obtained using Hewlett-Packard or Irex-Meridien instruments with a 2.5-MHz transducer. M-mode measurements were performed according to the recommendations of the committee of the American Society of Echocardiography.25 %FSH(LV) was determined using the following calculation:
(LV EDD-LV ESD)
%FSH(LV)=
x 100 LV EDD where LV EDD is left ventricular end-diastolic diameter, and LV ESD is left ventricular end-systolic diameter.
Analysis of Data
Human tissue. All data from human hearts were analyzed according to the following procedures. All muscles with cross-sectional areas of more than 1.5 mm2 were excluded from the study. Although a diameter of less than 1.1 mm2 (or a cross-sectional area of less than 0.94 mm2) is considered optimal for tissue oxygenation at 28-29°C and a stimulation rate of 0.2 Hz,2627 human trabecular muscles frequently exceed this size limitation. We therefore verified that DT produced by muscles in each group with a cross-sectional area between 1.1 and 1.5 mm2 did not differ from that produced by muscles with a crosssectional area of less than 1.1 mm2 (p=0.9 for atrial muscles from functionally normal hearts, p=0.09 for atrial muscles from failing hearts, and p=0.3 for ventricular muscles from failing hearts; KruskalWallis analysis). Additionally, muscles that showed a negative inotropic response to 10-6 M isoproterenol, (i.e., DT after 10-6 M isoproterenol less than the baseline value) were excluded from the study. Baseline contractile parameters (RT, DT, TPT, and T1,2R) were compared among the three groups of muscles using a Kruskal-Wallis analysis.
In response to cumulative doses of Ang 11 (10` A repeated-measures ANOVA was used to compare the responses of atrial and ventricular muscles from explanted hearts, and an ANOVA was also used to compare the mean responses at each dose. The responses of atrial muscles from explanted hearts and ventricular muscles from explanted hearts were each compared with those of atrial muscles from surgical patients using a nested ANOVA, which nested hearts within groups and muscles within hearts. Unless otherwise noted, all values are given as mean± SEM.
Hamster tissue. Data obtained from hamster cardiac muscle were analyzed as follows. Dose-response curves to Ang II for each of the contractile parameters were compared for papillary muscles from myopathic hearts and from normal hearts using a repeated-measures ANOVA. Responses of control papillary muscles and those treated with phentolamine and propranolol were compared using the same analysis. Results 
Human Trabecular Muscles Used
A total of 26 right atrial and 23 ventricular (20 right and three left) trabecular muscles were obtained from 13 cardiac transplant patients. Ten atrial and four ventricular muscles were eliminated from this group because of cross-sectional areas of more than 1.5 mm2. Four additional ventricular muscles were eliminated because their function declined over the course of the experiment. This left a total of 16 atrial and 15 ventricular muscles from 10 patients to be studied (Table 3) . A total of 16 atrial trabecular muscles were obtained from nine cardiac surgical patients. Four trabecular muscles were eliminated from this group because of cross-sectional areas of more than 1.5 mm2, leaving a total of 12 muscles from eight patients to be studied (Table 4) .
Baseline contractile data for human trabecular muscles are presented in Table 1 Ang II produced a dose-dependent increase in DT in all groups of human muscles (Figures lA-iC) . Considering all muscles in each of the groups, the dose-response relation was statistically significant in all three groups of muscles (p=0.05 for atrial trabeculae from failing hearts, p=0.02 for ventricular trabeculae from failing hearts, andp=0.04 for atrial trabeculae from functionally normal hearts). The increase in DT was accompanied by a significant decrease in RT in all three groups (p=0.01 for atrial trabeculae from functionally normal hearts, p= 0.0003 for atrial trabeculae from failing hearts, and p=0.0001 for ventricular trabeculae from failing hearts 
Effect ofAngiotensin II in Hamster Papillary Muscles
The average cross-sectional area of the hamster papillary muscles used in this study was 0.7 +0.2 mm2. Baseline DT recorded from hamster muscles was 1.3±0.2 (+SEM) g/mm2 for normal (n=8) and 0.3+0.07 g/mm2 for cardiomyopathic (n=9) muscles. Our baseline values for muscles from normal hamster hearts are comparable to those obtained by other investigators.32 In response to successive doses of Ang II, ventricular muscle from normal hamster hearts produced an increase in DT. Although an increase in DT was also observed in ventricular muscle from myopathic hamster hearts, the increase was significantly less than that observed in muscle from the normal hamster hearts (p<0.04, Figure 2 ). In both groups of hamster papillary muscles, the increase in DT was accompanied by a decrease in RT and no change in TPT or T1/2R. The dose/response curve to Ang II in normal papillary muscle was no different in the presence of the f3-adrenergic receptor antagonist propranolol and the a-adrenergic receptor antagonist phentolamine (Figure 3 In human atrial muscles, although Ang II caused no significant change in TPT, a significant, dosedependent increase in T1/2R (p=0.02 and 0.05 for atrial muscles from functionally normal hearts and failing hearts, respectively) was observed. The meaning of this increase in T1/2R is unclear. Although this pattern of responsiveness (increased DT, no change in TPT, and increased T1/2R) is different from other inotropic agents whose mechanism of action is known,29 the actions of most inotropic agents have been studied on ventricular tissue, and their effects on atrial tissue are less well characterized. Despite the fact that the mechanism of action of Ang II has not been definitely established, at least one recent study has suggested that its actions on the myocardium may be mediated by the activation of protein kinase C.38 Protein kinase C has been shown to phosphorylate phospholamban in the sarcoplasmic reticulum membrane,39 which could have an effect on sarcoplasmic reticulum Ca 2 uptake and, therefore, on the rate of relaxation, but this mechanism of action might be expected to shorten rather than lengthen T1,2R. Alternatively, protein kinase C may act via an undefined mechanism to decrease the rate of uptake of Ca2' by the sarcoplasmic reticulum, or the Ang II-mediated inotropic effect may involve the action of second messengers other than protein kinase C. The fact that T1/2R increased in response to (Table 2 ). These data suggest that muscle from failing hearts may be more sensitive to the inotropic effects of Ang II than is muscle from functionally normal hearts. This finding may be related to the demonstration of two classes of Ang II binding sites with different affinities in the guinea pig atrium'1 and the rabbit heart.13 The half-ir.iximal contractile response in human ventricular muscle in this study occurred at 5 x 10-9 M Ang II, which is close to the KD for the high-affinity Ang II binding site identified in the normal human left ventricle20 and the guinea pig" and rabbit13 hearts. Assuming a maximal or close-to-maximal response had been reached in atrial trabeculae at 10-5 M Ang II, the half-maximal response to Ang II can be calculated as .10`8 M Ang II (atrial trabeculae from explanted hearts) or .10`M Ang II (atrial trabeculae from surgical patients). The KD for the lowaffinity Ang II binding site was shown to be 3 x 10`7 M in guinea pig atrium" and 1 x 10`6 M in rabbit heart.13 Our data suggest that the human heart may also possess more than one type of binding site for Ang II and that the two classes of binding sites may exist in different chambers of the heart or may be regulated differentially during heart failure.
The inotropic response to Ang II appeared to be larger in both groups of atrial trabeculae than in ventricular trabeculae (Figure 1) , although the difference reached significance only when comparing atrial trabeculae from surgical patients with ventricular trabeculae, most likely due to the large variability in responsiveness in atrial trabeculae from failing hearts. The reason for the difference in responsiveness in atrial and ventricular muscle is unclear. The simplest explanation would be a difference in the number of Ang II receptors between the chambers of the heart. An increased number of Ang II receptors in the right atrium compared with both ventricles has been demonstrated in the normal human heart,20 but it remains to be established whether this pattern holds true in the diseased human heart. Alternatively, the increased inotropic response to Ang 11 in atrial muscle may result from intrinsic differences between the two types of muscle. The fact that Ang II causes a positive inotropic effect on cardiac muscle suggests that it elevates intracellular Ca'+. Several established differences between atrial and ventricular muscle imply that their mechanism of handling intracellular Ca'+ may be different. Calcium channels in the atria are predominantly of the T type, whereas those in th'; ventricles are mainly L-type channels. 41 This difference may be particularly relevant in light of the recent suggestion that Ang II can increase the current through the T-type calcium channels.42 Additionally, it has been demonstrated that atrial muscle is more sensitive than ventricular muscle to calcium influx from outside the cell.40 It might also be argued that atrial muscle from failing hearts is not as diseased as the ventricular muscle and that the inotropic response is therefore preserved. The data obtained from normal and myopathic hamsters in this study indicate that normal ventricular muscle exhibits a greater inotropic response to Ang II than does diseased ventricular muscle, but hamster atria still demonstrated a greater inotropic response to Ang II than did either group of ventricular muscles. We have previously demonstrated that the inotropic effect of endothelin43 is also greater in atrial muscle than in ventricular muscle from either human or rat hearts. 22 The greater inotropic response to Ang II in atrial muscle, therefore, may not be unique to Ang II but may be characteristic of many inotropic agents. Inotropic support to the atrium, especially in the case of a failing ventricle, may have physiological significance since increased contractility during atrial systole can augment ventricular diastolic filling. 44 Heterogeneity of Response of Human Trabeculae to Angiotensin II Although the inotropic response to Ang II, averaged over all human muscles in each group, is not large compared with the inotropic response to isoproterenol, the averaging of the data from all muscles may not be the most accurate representation of the cardiac muscle response to Ang II because of the demonstrated heterogeneity in responsiveness. Averaging the responses from only those muscles that showed a significant positive response to Ang II demonstrates the potential for a substantial positive inotropic response mediated by Ang II (Figures   lA-iC) . The reason for heterogeneity in Ang II responsiveness among muscles remains to be established. In some cases, responsive and nonresponsive muscles came from the same heart, which may relate to the finding of heterogeneity in receptor distribution throughout the human myocardium.20 A similar pattern of responsiveness to Ang II was observed by Kobayashi and coworkers10 in the canine myocardium, in which a positive inotropic response to Ang II was demonstrated in five of nine canine cardiac muscle strips, a negative response was seen in one strip, and no response was observed in three strips. In the human heart, Bruckner and coworkers45 described heterogeneity of responsiveness to the a-adrenergic agonist phenylephrine with positive inotropic responses in 14 left ventricular muscle preparations and a lack of response in the remaining 11 preparations. They were unable to explain this phenomenon on the basis of any known differences in muscles or patients. Since several studies have indicated that the intracellular actions of Ang 1111 and a-adrenergic agonists46 in cardiac muscle may both involve second-messenger pathways related to the breakdown of membrane phospholipids, the data from this study taken with those of Bruckner et al's study could suggest that a component of the phosphatidyl inositol signalling pathway may be disrupted during human heart disease.
Among individual muscle characteristics that might explain the observed heterogeneity in response, the fact that there was no relation between Ang II response and cross-sectional area of the muscles indicates that Ang II responsiveness was unrelated to the degree of oxygenation of the muscle preparation in vitro. We investigated a possible relation between muscle cross-sectional area and DT since larger muscles may not be as well oxygenated in vitro and also since it has been suggested that Ang II or its analogues may actually be more effective inotropic agents during hypoxia. 47 However, this analysis revealed that Ang II responsiveness was not related to muscle size. There was also no relation between baseline RT, DT, or T1,2R and Ang II responsiveness in any of the groups of muscles, indicating that heterogeneity of responsiveness to Ang II cannot be attributed to a difference in baseline performance or to random damage during dissection. In atrial trabeculae, there was also no correlation between baseline TPT and response to Ang II, but a relation was demonstrated between these two variables in ventricular trabeculae (i.e., muscles that required a longer time to reach maximal tension responded better to inotropic stimulation by Ang II). Several (Table 2) . Additionally, the maximal increase in DT attained in response to Ang II was greatest in atrial trabeculae from functionally normal hearts. It is unlikely that muscle from explanted hearts was more damaged as a result of the transplant procurement procedure than muscle obtained from surgery as there was no significant difference between the baseline parameters of contraction measured in atrial trabeculae from either source ( Table 1) . The fact that a larger percentage of muscles from surgical patients was responsive to Ang II may imply that although heterogeneity of responsiveness to Ang II does exist in the normal myocardium, the process of cardiac disease has an additional effect on the inotropic response. This contention is supported by the data from the hamster hearts, in which cardiac muscle from normal hearts showed a significantly greater inotropic response to Ang II than did cardiac muscle from the failing hearts of myopathic hamsters. Since Ang II receptor numbers in the human heart20 and cardiomyopathic hamster hearts18 have been shown to be unchanged by heart failure, this decreased responsiveness could be the result of an alteration distal to the receptor. The decreased response could be due to alterations in the uptake of Ca2' by the sarcoplasmic reticulum in heart failure303150 and an inability to influence the rate of uptake. Alternatively, a defect in another component of the signalling pathway, similar to the increase in GC that is believed to be partially responsible for decreased responsiveness to 13-adrenergic agonists in cardiac muscle from heart failure patients,5 could result in diminished responsiveness to Ang II in failing hearts.
The reason for the heterogeneity of Ang II responsiveness in the human myocardium (which was not observed in the hamster heart) has not been established by these studies and will need further investigation. Possible reasons that have not been addressed here might include the level of sodium in the diet, which has been shown to modulate inotropic responsiveness to Ang II,5 and the stimulation of prostaglandin release by Ang 11,52-55 which could modify the effects of Ang II on contractile force. [56] [57] [58] The physiological significance of an inotropic response to Ang II remains to be established. In light of the discovery of a local renin-angiotensin system within the myocardium,34 it is reasonable to hypothesize that fairly high concentrations of Ang II could be achieved locally in the heart without the deleterious vasoconstrictor effects of circulating Ang II. That is, sites of Ang II action in the heart may be compartmentalized. Additionally, the demonstration that Ang II formation in the heart may occur via an alternative converting enzyme that is insensitive to captopril59 implies that local levels of Ang II in the heart could remain high despite therapeutic intervention with Ang II converting enzyme inhibitors.
While some may argue that deleterious effects on the coronary vasculature would arise from such locally high concentrations of Ang II, the question of the effects of Ang II on the coronary arteries in vivo has not been fully resolved. In particular, there is some evidence to support the hypothesis that Ang II releases prostaglandin E2 and prostacyclin from the endothelial lining of coronary blood vessels50-52 and that these prostaglandins, although they have only minimal vasodilatory actions under baseline conditions, may be potent vasodilators in the case of prior vasoconstriction. 60 The balance between the vasoconstrictor actions of Ang II and the vasodilator actions of the prostaglandins would then determine the degree of coronary blood flow. Some experimental evidence supports Ang Il-dependent vasodilation6061 or only minimal vasoconstriction62 in the coronary vasculature and shows that pretreatment with indomethacin significantly increases the Ang II vasoconstrictor effects on coronary arteries. 61 The balance of vasoconstrictor and vasodilator effects may change as heart failure progresses and vasodilator mechanisms become limited,60 but coronary vasoconstriction may not be a limitation of Ang IImediated inotropic support to the heart, at least in the early stages of heart failure.
In summary, our demonstration of a direct inotropic action of Ang II on human myocardium in both diseased and healthy hearts may suggest an important cardiac action of this naturally occurring peptide under both physiological and pathological conditions in addition to and independent of its vascular and hemodynamic effects.
